Trial reportAsian journal of andrology2013
Multivariate analysis to predict letrozole efficacy in improving sperm count of non-obstructive azoospermic and cryptozoospermic patients: a pilot study.
Trial report in Asian journal of andrology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Pharmacological non-hormonal treatment options for male infertility: a systematic review and network meta-analysis.BMC urology · 2024Pooled it
- Does hormonal therapy improve sperm retrieval rates in men with non-obstructive azoospermia: a systematic review and meta-analysis.Human reproduction update · 2022Pooled it
- A systematic review and meta-analysis of clinical trials implementing aromatase inhibitors to treat male infertility.Asian journal of andrologyPooled it
- Effect of Letrozole on sperm parameters, chromatin status and ROS level in idiopathic Oligo/Astheno/Teratozoospermia.Reproductive biology and endocrinology : RB&E · 2020Trial
- Micro-TESE in Non-Obstructive Azoospermia: Phenotype-Guided Hormonal Optimization and Testosterone Response-Prognostic Biomarker or Therapeutic Target?Journal of clinical medicine · 2026Review
- Treatment with isotretinoin can improve de novo sperm production in nonobstructive azoospermia or cryptozoospermia.Journal of assisted reproduction and genetics · 2025Article
- Medical treatment prior to micro-TESE.Asian journal of andrology · 2025Review
- Strategies in Infertile Azoospermic Patients with Negative Microdissection Testicular Sperm Extraction Surgery.Urology research & practice · 2023Article
- Review
- Effect of Letrozole Administration as a Selective Aromatase Inhibitor on Male Rat's Reproductive Performance.Archives of Razi Institute · 2022Article
- Morphological and morphometric changes and epithelial apoptosis are induced in the rat epididymis by long-term letrozole treatment.European journal of histochemistry : EJH · 2021Article
- Male infertility due to testicular disorders.The Journal of clinical endocrinology and metabolism · 2021Review
- Microdissection testicular sperm extraction.Translational andrology and urology · 2017Review
- Diagnosis and treatment of infertility-related male hormonal dysfunction.Nature reviews. Urology · 2016Review
- Empiric medical therapy with hormonal agents for idiopathic male infertility.Indian journal of urology : IJU : journal of the Urological Society of IndiaReview
- Efficacy and Safety of Letrozole in Improving Semen Parameters of Subfertile Men with Moderate-to-Severe Oligoasthenoteratozoospermia: A Placebo-controlled Randomised Trial.Journal of human reproductive sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We tested the hypothesis that letrozole increases sperm count in non-obstructive azoospermic or cryptozoospermic patients with a testosterone (T)/17-beta-2-oestradiol (E2) ratio <10. Forty-six patients with no chromosomal aberrations were randomized into two groups: 22 received letrozole 2.5 mg per day for 6 months (Group 1: 6 azoospermic + 16 cryptozoospermic patients), while 24 received a placebo (Group 2: 5 azoospermic + 19 cryptozoospermic patients). The following data were collected: two semen analyses, clinical history, scrotal Duplex scans, body mass index (BMI), Y microdeletion, karyotype and cystic fibrosis screens and follicle-stimulating hormone (FSH), luteinizing hormone (LH), E2, T and prolactin levels. Both before and after letrozole or placebo administration, the patients underwent two semen analyses and hormonal assessments. The differences were evaluated using the Mann-Whitney U test. The relationships between sperm concentration after letrozole administration with respect to FSH, T/E2 ratio, bilateral testicle volume and BMI before letrozole administration were assessed using multivariate analysis. The side effects were assessed using the chi-square test. Group 1 had sperm concentration (medians: 400-1.290 × 10(6) ml(-1); P<0.01) and motility (medians: class A from 2% to 15%; P<0.01), FSH, LH and T significantly increased, while Group 2 did not. E2 levels diminished significantly in Group 1, but not in Group 2. Eight patients in Group 1 demonstrated side effects, whereas no patient side effects were observed in Group 2. The sperm concentration after letrozole administration is inversely related to T/E2, FSH and BMI; a direct relationship emerged between sperm concentration and testicular volume.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.